Giovenzio Genestreti

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo et al. · Journal of Clinical Oncology · 2012 · 234 citations · Full text

Medicine, Oncology, Pharmacology +16

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

Nicola Giuliani, Simona Colla, Mirca Lazzaretti et al. · Blood · 2003 · 109 citations · Full text

Medicine, Cell Biology, Oncology +14

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Giovenzio Genestreti, Marcello Tiseo, Hirotsugu Kenmotsu et al. · Clinical Lung Cancer · 2015 · 61 citations

Medicine, Oncology, Pharmacotherapy +13

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

Andrea Ardizzoni, Marcello Tiseo, Luca Boni et al. · Journal of Clinical Oncology · 2012 · 52 citations

Medicine, Oncology, Pharmacology +12

International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

Cesare Gridelli, Fortunato Ciardiello, R. Feld et al. · Journal of Clinical Oncology · 2010 · 46 citations

Medicine, Oncology, Pharmacology +13